Nexalin Technology Ownership
| NXL Stock | USD 2.48 0.03 1.22% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Nexalin |
Nexalin Stock Ownership Analysis
About 19.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.83. Nexalin Technology had not issued any dividends in recent years. Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company was incorporated in 2021 and is headquartered in Houston, Texas. Nexalin Technology operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Nexalin Technology contact Mark White at 832 260 0222 or learn more at https://www.nexalin.com.Besides selling stocks to institutional investors, Nexalin Technology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Nexalin Technology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Nexalin Technology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Nexalin Technology Quarterly Liabilities And Stockholders Equity |
|
Nexalin Technology Insider Trades History
About 19.0% of Nexalin Technology are currently held by insiders. Unlike Nexalin Technology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Nexalin Technology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Nexalin Technology's insider trades
Nexalin Technology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nexalin Technology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nexalin Technology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nexalin Technology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nexalin Technology Corporate Filings
10K | 14th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F5 | 10th of February 2025 The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners | ViewVerify |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nexalin Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Nexalin Stock please use our How to buy in Nexalin Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexalin Technology. If investors know Nexalin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexalin Technology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth 0.323 | Return On Assets | Return On Equity |
The market value of Nexalin Technology is measured differently than its book value, which is the value of Nexalin that is recorded on the company's balance sheet. Investors also form their own opinion of Nexalin Technology's value that differs from its market value or its book value, called intrinsic value, which is Nexalin Technology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexalin Technology's market value can be influenced by many factors that don't directly affect Nexalin Technology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nexalin Technology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexalin Technology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexalin Technology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.